Synthesis of tricyclic compounds as steroid 5α-reductase inhibitors

Chemical and Pharmaceutical Bulletin

Volumn 48, Issue 4, 2000, Pages 552-555

  Takami, Hitoshi ^a   Nonaka, Hiromi ^a   Kishibayashi, Nobuyuki ^a   Ishii, Akio ^a   Kase, Hiroshi ^a   Kumazawa, Toshiaki ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

5 reductase; Benign prostatic hyperplasia; Structure activity relationship; Substituent effect; Tricyclic compounds

Indexed keywords

4 [3 [5 BENZYL 8 (2 METHYL)PROPYL 10,11 DIHYDRODIBENZ[B,F]AZEPINE 2 CARBOXAMIDO]PHENOXY]BUTYRIC ACID; STEROID 5ALPHA REDUCTASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; DRUG POTENCY; DRUG SYNTHESIS; ENZYME INHIBITION; LIPOPHILICITY; NONHUMAN; PROSTATE HYPERTROPHY; RAT; STRUCTURE ACTIVITY RELATION;

EID: 0034058640     PISSN: 00092363     EISSN: None     Source Type: Journal    
DOI: 10.1248/cpb.48.552     Document Type: Article

References (21)

1. a) Metcalf B. W., Levy M. A., Holt D. A., Trends Pharmacol. Sci., 10, 491 (1989);
2. b) Geller J., Prostate, Suppl., 2, 95 (1989);
3. c) Isaacs J. T., Brendler C. B., Walsh P. C., J. Clin. Invest., 56, 139 (1983).
4. Sansone G. L., Reisner R. M., J. Invest. Dermatol., 56, 366 (1971).
5. Diani A. R., Mulholland M. J., Shull K. L., Kubicek M. F., Johnson G. A., Schostarez H. J., Brunden M. N., Buhl A. E., J. Clin. Endocrinol. Metab., 74, 345 (1992).
6. Brooks J. R., J. Clin. Endocrinol. Metab., 15, 391 (1986).
7. Russel D. W., Wilson J. D., Annu. Rev. Biochem., 63, 25 (1994).
8. a) Kumazawa T., Takami H., Kishibayashi N., Ishii A., Nagahara Y., Hirayama N., Obase H., J. Med. Chem., 38, 2887 (1995);
9. b) Takami H., Koshimura H., Kishibayashi N., Ishii A., Nonaka H., Aoyama S., Kase H., Kumazawa T., J. Med. Chem., 39, 5047 (1996);
10. Takami H., Kishibayashi N., Ishii A., Kumazawa T., Bioorg. Med. Chem., 6, 2441 (1998).
11. Nakai H., Terashima H., Arai Y., EP 0291245 (1988) [Chem. Abstr., 110, 212384t, 708 (1989)].
12. a) Yoshioka T., Kitagawa M., Oki M., Kubo S., Tagawa H., Ueno K., J. Med. Chem., 21, 633 (1978);
13. b) Tagawa H., Kubo S., Ishikawa F., Chem. Pharm. Bull., 29, 3515 (1981).
14. a) Sallmann A., Pfister R., Chem. Abstr., 76, 11322k, 893 (1972);
15. b) Ito C., Okahana N., Wu T.-S., Wang M.-L., Lai J.-S., Kuoh C.-S., Furukawa H., Chem. Pharm. Bull., 40, 230 (1992).
16. Bald E., Saigo K., Mukaiyama T., Chem. Lett., 1163 (1975).
17. a) Andersson S., Berman D. M., Jenkins E. P., Russell D. W., Nature (London) 354, 159 (1991);
18. b) Jenkins E. P., Andersson S., Imperato-McGinley J., Wilson J. D., Russell D. W., J. Clin. Invest., 89, 293 (1992).
19. a) Leo A. J., Chem. Rev., 93, 1281 (1993);
20. b) The values were calculated by C log P for Windows Ver. 1.0.0 (BioByte Corp.).
21. Takami H., Ohshima E., Sato H., Kumazawa T., Miki I., Ishii A., Sasaki Y., Ohmori K., Karasawa A., Kubo K., Obase H., Abstracts of Papers, 13rd Medicinal Chemistry Symposium/2nd Annual Meeting of Division of Medicinal Chemistry, Tokyo, November 1992, paper 35.